SUPN

Supernus Pharmaceuticals (SUPN)

About Supernus Pharmaceuticals (SUPN)

Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. The company was founded by Jack A. Khattar on March 30, 2005, and is headquartered in Rockville, MD.

Details

Daily high

$52.59

Daily low

$50.36

Price at open

$52.46

52 Week High

$59.68

52 Week Low

$30.83

Market cap

3.0B

Dividend yield

0.00%

Volume

83,635

Avg. volume

694,326

P/E ratio

-102.13

Supernus Pharmaceuticals News